JP2007515422A5 - - Google Patents

Download PDF

Info

Publication number
JP2007515422A5
JP2007515422A5 JP2006545506A JP2006545506A JP2007515422A5 JP 2007515422 A5 JP2007515422 A5 JP 2007515422A5 JP 2006545506 A JP2006545506 A JP 2006545506A JP 2006545506 A JP2006545506 A JP 2006545506A JP 2007515422 A5 JP2007515422 A5 JP 2007515422A5
Authority
JP
Japan
Prior art keywords
composition
use according
pharmacologically active
active derivative
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006545506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/042562 external-priority patent/WO2005063249A1/en
Publication of JP2007515422A publication Critical patent/JP2007515422A/ja
Publication of JP2007515422A5 publication Critical patent/JP2007515422A5/ja
Pending legal-status Critical Current

Links

JP2006545506A 2003-12-22 2004-12-17 糖尿病性網膜症および黄斑変性における結晶腔形成の処置のための薬剤 Pending JP2007515422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53181103P 2003-12-22 2003-12-22
PCT/US2004/042562 WO2005063249A1 (en) 2003-12-22 2004-12-17 Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration

Publications (2)

Publication Number Publication Date
JP2007515422A JP2007515422A (ja) 2007-06-14
JP2007515422A5 true JP2007515422A5 (https=) 2007-10-18

Family

ID=34738705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006545506A Pending JP2007515422A (ja) 2003-12-22 2004-12-17 糖尿病性網膜症および黄斑変性における結晶腔形成の処置のための薬剤

Country Status (9)

Country Link
US (2) US20050137147A1 (https=)
EP (1) EP1696926A1 (https=)
JP (1) JP2007515422A (https=)
AU (1) AU2004308911B2 (https=)
BR (1) BRPI0417996A (https=)
CA (1) CA2548146A1 (https=)
MX (1) MXPA06006862A (https=)
WO (1) WO2005063249A1 (https=)
ZA (1) ZA200605378B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06006980A (es) * 2003-12-22 2006-12-14 Alcon Inc Agentes para tratamiento de retinopatia glaucomatosa y neuropatia optica.
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
JPWO2006030907A1 (ja) * 2004-09-16 2008-05-15 レドックス・バイオサイエンス株式会社 網膜保護剤
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
FR2902326B1 (fr) * 2006-06-20 2008-12-05 Oreal Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie
WO2008016095A1 (en) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20090324740A1 (en) * 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
JP5734869B2 (ja) * 2008-12-16 2015-06-17 オンコノバ・セラピューティックス・インコーポレーテッド ヒトにおける細胞毒性物質の有害作用に対する治療レジメンの有効性を決定する方法
WO2012009171A2 (en) * 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
WO2014179568A2 (en) 2013-05-02 2014-11-06 Odin Biotech Two-layer ocular implant
EP3919052A4 (en) * 2019-01-09 2022-10-05 Fuso Pharmaceutical Industries, Ltd. Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
CN112716938A (zh) * 2021-02-25 2021-04-30 新疆医科大学 鞣花酸在制备缓解眼组织病变的药物中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
ATE289815T1 (de) * 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
ES2205166T3 (es) * 1996-02-02 2004-05-01 D. Western Therapeutics Institute Derivados de isoquinolina y medicamento.
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
BR9711154A (pt) * 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6441033B1 (en) * 1997-12-22 2002-08-27 Alcon Manufacturing, Ltd. 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
US5958946A (en) * 1998-01-20 1999-09-28 Styczynski; Peter Modulation of hair growth
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US20010041174A1 (en) * 1998-11-24 2001-11-15 Najam Sharif Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases
US6020383A (en) * 1999-01-11 2000-02-01 Eastman Chemicals Company Method for reducing blood cholesterol and/or blood triglycerides
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
WO2002002190A2 (en) * 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
GB0030727D0 (en) * 2000-12-15 2001-01-31 Lumitech Uk Ltd Methods and kits for detecting kinase activity
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US7199122B2 (en) * 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
US7247714B2 (en) * 2001-10-16 2007-07-24 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
WO2003051313A2 (en) * 2001-12-18 2003-06-26 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
US20030219846A1 (en) * 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma

Similar Documents

Publication Publication Date Title
US20230285329A1 (en) Methods and Compositions for the Treatment of Steatosis-Associated Disorders
Baluchnejadmojarad et al. Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress
JP2007515423A5 (https=)
Yerra et al. Isoliquiritigenin reduces oxidative damage and alleviates mitochondrial impairment by SIRT1 activation in experimental diabetic neuropathy
Bhattacharya et al. Anti‐stress activity of sitoindosides VII and VIII, new acylsterylglucosides from Withania somnifera
JP2007515422A5 (https=)
Sharma et al. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51
Singh et al. Verapamil augments the neuroprotectant action of berberine in rat model of transient global cerebral ischemia
Wolf et al. Amphetamine‐induced glutamate efflux in the rat ventral tegmental area is prevented by MK‐801, SCH 23390, and ibotenic acid lesions of the prefrontal cortex
El-Bassossy et al. Chrysin and luteolin alleviate vascular complications associated with insulin resistance mainly through PPAR-γ activation
Mastalerz et al. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin‐induced asthma
CA2443229A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
Tschiffely et al. A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease
KR20120058457A (ko) 근육감소증의 예방 및 치료
US20130045988A1 (en) Combination therapy
Cui et al. Syringin may exert sleep‐potentiating effects through the NOS/NO pathway
Candelario-Jalil et al. Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia
CN107441104A (zh) 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途
Meltzer et al. Efficacy and safety of ciclesonide, 200 μg once daily, for the treatment of perennial allergic rhinitis
CN111727040A (zh) 用于改善认知能力或认知功能的尿石素a和b的协同组合
Chang et al. Alpha-lipoic acid attenuates silica-induced pulmonary fibrosis by improving mitochondrial function via AMPK/PGC1α pathway activation in C57BL/6J mice
Chipana et al. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents
Shivkar et al. Histamine mediates the pro‐inflammatory effect of latex of Calotropis procera in rats
Fujita et al. Involvement of cysteinyl leukotrienes in biphasic increase of nasal airway resistance of antigen-induced rhinitis in guinea pigs
Woynillowicz et al. The effect of smoking cessation pharmacotherapies on pancreatic beta cell function